Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout

被引:13
作者
Bisht, Manisha [1 ]
Bist, S. S. [1 ]
机构
[1] HIHT Univ, Himalayan Inst Med Sci, Dept Pharmacol & ENT, Dehra Dun 248140, Uttar Pradesh, India
关键词
Gout; hyperuricemia; xanthine oxidase inhibitor; XANTHINE OXIDASE/XANTHINE DEHYDROGENASE; PURINE SELECTIVE INHIBITOR; PHASE-III; JAPANESE SUBJECTS; CLINICAL-TRIAL; DOUBLE-BLIND; SERUM URATE; ALLOPURINOL; OXIDASE; PLACEBO;
D O I
10.4103/0250-474X.100231
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gout is a metabolic disorder characterized by elevated uric acid levels in the body, associated with painful arthritis, tophi and nephropathy. The most frequently used pharmacologic urate lowering strategies involve reducing urate production with a xanthine oxidase inhibitor and enhancing urinary excretion of uric acid with a uricosuric agent. Urate lowering agents are limited in number, availability and effectiveness. The emergence of a new medication, febuxostat, to lower serum urate levels is welcome as no new drug have been approved since the introduction of allopurinol, in 1964, and the drugs that are available have limitations owing to inefficacy or toxicity. Febuxostat is a novel, nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.
引用
收藏
页码:597 / 600
页数:4
相关论文
共 18 条
  • [1] Endophthalmitis
    Becker, M.
    [J]. SPEKTRUM DER AUGENHEILKUNDE, 2008, 22 (01) : 3 - 3
  • [2] Becker M., 2005, Arthritis and allied conditions, V15, P2303
  • [3] Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers
    Becker, MA
    Kisicki, J
    Khosravan, R
    Wu, J
    Mulford, D
    Hunt, B
    MacDonald, P
    Joseph-Ridge, N
    [J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9) : 1111 - 1116
  • [4] Febuxostat compared with allopurinol in patients with hyperuricemia and gout
    Becker, MA
    Schumacher, HR
    Wortmann, RL
    MacDonald, PA
    Eustace, D
    Palo, WA
    Streit, J
    Joseph-Ridge, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) : 2450 - 2461
  • [5] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase
    Becker, Michael A.
    Schumacher, H. Ralph, Jr.
    Wortmann, Robert L.
    MacDonald, Patricia A.
    Palo, William A.
    Eustace, Denise
    Vernillet, Laurent
    Joseph-Ridge, Nancy
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (03): : 916 - 923
  • [6] CADA DJ, 2009, HOSP PHARM, V44, P688
  • [7] Horiuchi H, 1999, RES COMMUN MOL PATH, V104, P307
  • [8] Kamatani N, 2003, ARTHRITIS RHEUM, V48, pS530
  • [9] Kamatani N, 2004, ARTHRITIS RHEUM, V50, pS336
  • [10] Kamatani N, 2004, ARTHRITIS RHEUM, V50, pS337